AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02488135 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Floseal Hemostatic Matrix
Description: Floseal Hemostatic Matrix is a gel like fibrin glue used topically in the nasal cavity and applied with a syringe.
Study NCT02488135 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Nasal Packing
Description: Using either vaseline gauze or nasal merocels. These will be placed in the anterior nasal cavity using nasal speculum and forceps.
Study NCT01027494 — intervention group
Intervention type: DRUG
Intervention: Ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension
Description: Four drops in the outer ear canal of infected ear(s) while awake 2 times per day for 7 days
Study NCT01773005 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ofirmev
Description: Subject receives the interventional drug, intravenous ibuprofen (800 mg Caldolor) at the induction of anesthesia and intravenous Acetaminophen (1000 mg Ofirmev) at the time of surgical wound closure, followed by 800 mg Caldolor plus 1000 mg Ofirmev every 6 hours until discharge for a total of up to 120 hours (5 days)
Study NCT01773005 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Caldolor
Description: Subject receives the interventional drug, intravenous ibuprofen (800 mg Caldolor) at the induction of anesthesia, followed by 800 mg Caldolor every 6 hours until discharge or for a total of up to 120 hours (5 days)
Study NCT01773005 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caldolor
Description: Subject receives the interventional drug, intravenous ibuprofen (800 mg Caldolor) at the induction of anesthesia, followed by 800 mg Caldolor every 6 hours until discharge or for a total of up to 120 hours (5 days)
Study NCT02144688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Change in antiretrovirals
Description: Change in ARVs to improve cognition: Personalized change in antiretrovirals will be based on CSF analysis
Study NCT04164095 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: lappg
Description: Preservation of pylorus and vagus nerve by laparoscopy
Study NCT04164095 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lappg
Description: Preservation of pylorus and vagus nerve by laparoscopy
Study NCT03756155 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: isometric intervention
Description: The research participants will perform isometric repetitions against the hand held dynamometer
Study NCT04244773 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ENDS (vaporizer/e-cig) and smoking cessation counseling
Description: Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
Study NCT04244773 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Smoking cessation counseling
Description: Participants in the control group will receive smoking cessation counseling only. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
Study NCT01466855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intra-Ophthalmic Artery Topotecan Infusion
Description: Topotecan via intra-ophthalmic artery delivery infused over 30 minutes on Day 1 of every 21-day cycle.
Study NCT03423095 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Active Jaw Exercise with Relaxation
Description: This is the control group that will complete exercises unrelated to the primary outcome measures.
Study NCT03423095 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Tongue Exercise
Description: This is the active comparator group that will complete exercises already shown to increase tongue strength measures.
Study NCT03423095 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active Tongue Exercise + Mental Practice
Description: This is an experimental group that will complete active tongue and mental tongue exercises to assess effect on tongue strength measures.
Study NCT03423095 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mental Practice Tongue Exercise
Description: This is an experimental group that will complete mental tongue exercises only to assess effect on tongue strength measures.
Study NCT01754623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Treatment will begin with the first round of chemotherapy. Each round of chemotherapy will take 21 days. Each round or cycle will start with participants taking capecitabine pills. Participants will take tablets of capecitabine (Xeloda®) twice per day for 14 days followed by 7 days without capecitabine.
Study NCT01754623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: On the fourth day of the cycle, participants will be treated with gemcitabine and docetaxel. First, this will consist of placing gemcitabine (Gemzar®) in a bag of fluid and giving it by vein over 30 minutes.
Study NCT01754623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: On the fourth day of the cycle, participants will be treated with gemcitabine and docetaxel. After the gemcitabine, participants will receive docetaxel (Taxotere®) in a bag of fluid over 1 hour.
Study NCT01754623 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation therapy (SBRT)
Description: 30/40 Gy to pancreatic tumor/area of borderline resectability
Study NCT01754623 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Restaging review after radiation
Description: After radiation, participants will be re-evaluated for surgery. Patients who have Complete Response (CR), Partial Response (PR) or stable disease (SD) will proceed with surgical exploration and resection provided they are suitable fit for surgery in the judgment of the surgical oncologist. Patients who have local progression on imaging scan will be offered conventional 5-Fluorouracil based intensity-modulated radiation therapy (IMRT). If no surgery: then chemotherapy. If surgery: chemotherapy will be given based on response.
Study NCT01754623 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Non-metastatic patients who are deemed resectable after neoadjuvant therapy will be taken to surgery. After surgery, chemotherapy will be given based on response.
Study NCT01754623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: Patients who have local progression on imaging scan will be offered conventional 5-Fluorouracil based intensity-modulated radiation therapy (IMRT).
Study NCT01440166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug
Description: Single dose oral administration of CAT1004 or placebo-6 to 8 subjects will be treated with CAT-1004 per cohort.
Study NCT04964310 — intervention group
Intervention type: GENETIC
Intervention: genetic polymorphism
Description: Observe the genetic polymorphism frequency difference between case and control groups
Study NCT04219943 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Treatment for Impacted Femoral Neck Fracture
Description: Surgical Treatment for Impacted Femoral Neck Fracture
Study NCT00818818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meglumine antimoniate
Description: 5mg/kg/d of pentavalent antimony, IV, for 20 consecutive days
Study NCT01983436 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Lymphatic drainage
Description: Manual lymphatic drainage of the face and the neck is a massage technique that aims to remove an edema of this anatomical region. The technique consists to stimulate the lymph nodes in order to accelerate the lymph flow and to achieve a specific massage to promote the entry of lymph nodes in the initial lymphatics. Massages follow anatomical pathways of vessels and of lymph nodes of the head and the neck. The technique should be smooth and painless.
Study NCT00850564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Growth Hormone Releasing Hormone (Tesamorelin)
Description: Tesamorelin 2mg subcutaneous daily x 2 weeks
Study NCT01031069 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' HPV vaccine 580299
Description: Subjects received three doses of the study vaccine administered intramuscularly according to a Day 0, Week 6, and Month 6 vaccination schedule.
Study NCT01031069 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Merck's Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine (Gardasil)
Description: Subjects received three doses of the study vaccine administered intramuscularly according to a Day 0, Week 6, and Month 6 vaccination schedule.
Study NCT01725334 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation
Description: Deep Brain Stimulation (DBS) is a surgical procedure involving the implantation of a thin flexible wire called a lead. This device sends mild electric signals to an area of the brain. This study targets two different areas that we believe may be responsible for negative symptoms observed in patients with schizophrenia. There are two stages to DBS: (1) Insertion of the DBS electrodes (2) The connection of these electrodes to a battery under the collarbone.
Study NCT05578391 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Convalescent plasma
Description: Admistration of one unit of convalescent plasma
Study NCT01032005 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: double fortified salt
Description: Refined salt of particle size \< 1 mm iodized with potassium iodate (KIO3) at a concentration of 30 µg I/g salt at the factory will be purchased and blended with encapsulated Ferrous Fumarate premix containing 15% iron. Premix to salt ratio of 1 to 150 will be used to arrive at 1000 ppm elemental iron in the final product.
Study NCT01032005 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: double fortified salt
Description: Refined salt of particle size \< 1 mm iodized with potassium iodate (KIO3) at a concentration of 30 µg I/g salt at the factory will be purchased and blended with encapsulated Ferrous Fumarate premix containing 15% iron. Premix to salt ratio of 1 to 150 will be used to arrive at 1000 ppm elemental iron in the final product.
Study NCT03918720 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trekkers Family Health Empowerment Programme
Description: Health Assessment, Health Enablement and Health Literacy provided to empower participants awareness towards a healthier life style
Study NCT01440166 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single dose oral administration of CAT1004 or placebo- 2 subjects treated with placebo per cohort.
Study NCT04422405 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: One Anastomosis Gastric Bypass (OAGB)
Description: The procedure is performed laparoscopically. The GIA stapler divides the stomach at the junction of the body and antrum. An Ewald tube, roughly the diameter of the esophagus, is passed by the anesthetist and held against the lesser curvature. The division of the stomach against the tube is completed, with 5- 6 lines of staples. The division of the stomach is parallel to the lesser curvature and up to the angle of His. A point is selected on the small bowel about 200 cm distal to the ligament of Treitz. The jejunal loop is brought up antecolic, and the Endo-GIA stapler is used to perform the anastomosis between the stomach and the small bowel at this point. The distal end of the gastric tube is anastomosed to the side of the small bowel.
Study NCT02455765 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rice and Amino Acid mixtures
Description: Rice and amino acid mixture
Study NCT06660251 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Egg intervention
Description: Oral administration of three hard-boiled eggs to be ingested within 15 minutes on one occasion.
Study NCT06660251 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Meatball intervention
Description: Oral intervention with 170 g meatballs to be ingested within 15 minutes on one occasion.
Study NCT01611337 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: insight variation measure
Description: insight variation between the firt week of hospitalization and 1 month later
Study NCT03342820 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Muscle fatigue
Description: Isokinetic quadriceps muscle fatigue of the paretic lower limb
Study NCT03066609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg s.c.
Description: 150 mg s.c. at randomization, Weeks 1, 2, 3, 4 and every 4 weeks till Week 48
Study NCT03066609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg s.c.
Description: 300 mg s.c. at randomization, Weeks 1, 2, 3, 4 and every 4 weeks till Week 48
Study NCT03066609 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 150 or 300 mg s.c at randomization, Weeks 1, 2, 3, 4, and 8. PASI responders at week 12 continued to receive placebo till Week 48. PASI non-responders at Week 12 received Secukinumab 300mg at Weeks 12, 13, 14, 15, 16 and every 4 weeks till Week 48
Study NCT04004494 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3D reconstruction
Description: 3-dimensional computed tomography reconstruction guided VATS segmentectomy
Study NCT03355573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimekizumab
Description: Bimekizumab at a prespecified dose.
Study NCT01025167 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Supportan(R) (Disease-specific enteral tube feed, food for special medical purposes)
Description: 500 ml per day / treatment period 11-14 weeks
Study NCT01025167 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Fresubin(R)
Description: 500 ml/a nutritionally complete enteral standard feed (isoenergetic)
Study NCT01567605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine lubricant
Description: Subjects using this intervention will receive 30 mL of Lidocaine hydrochloride jelly (2%)
Study NCT01567605 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lidocaine lubricant
Description: Subjects using this intervention will receive 30 mL of Lidocaine hydrochloride jelly (2%)
Study NCT01567605 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo lubricant
Description: Subjects using this intervention will receive 30 mL of placebo lubricant (no topical anesthetic)
Study NCT01567605 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo lubricant
Description: Subjects using this intervention will receive 30 mL of placebo lubricant (no topical anesthetic)
Study NCT02284113 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iovera°
Description: Use of iovera° device to administer treatment Focused Cold Therapy
Study NCT03210168 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BioFe Medical Food
Description: BioFe is comprised of cultured nutritional/Baker's yeast (Saccharomyces cerevisiae) with high levels of Ferritin/Iron complex, pasteurized, and dried
Study NCT03579732 — intervention group
Intervention type: DRUG
Intervention: Aspirin (Acetylsalicylic Acid, BAYE4465)
Description: Low dose of aspirin, i.e. \< 150 mg daily
Study NCT03579732 — intervention group
Intervention type: OTHER
Intervention: No drug
Description: Non-consumers
Study NCT02284113 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: iovera° Sham
Description: iovera° device used for sham treatment
Study NCT04388800 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Confront and Navigate Depression Online (CANDO)
Description: This study adopts a blended mode of service delivery, which included both online and offline intervention. The online intervention includes 8 weekly online model, animation briefing and debriefing, case demonstration video, exercise, forum, internal messaging, reminder, online assessment, session review and online booking system. The offline intervention includes two face-to-face sessions and two telephone follow-ups.
Study NCT02486432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodopa/Carbidopa (Sinemet)
Description: Oral administration of 2 × 12.5 mg/50 mg Sinemet® tablet containing 13.5 mg carbidopa (equivalent to 12.5 mg anhydrous carbidopa) and 50 mg levodopa three times a day on Day -1 with 240 mL water Oral administration of 1 × 12.5 mg/50 mg Sinemet® tablets containing 13.5 mg carbidopa (equivalent to 12.5 mg of anhydrous carbidopa) and 50 mg levodopa administered with 100 mL water every hour for 16 hours on Day 1
Study NCT03117699 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: New device for seated-standing passages
Description: Phase 1 : The subject perform different seated-standing passages (see Arm)~Phase 2 : After being seated, the subject performs a course comprising:~* A standing pass from sitting on a chair~* A straight line movement~* A succession of left and right turns~* An upward and downward travel of less than 1%.~* Standard doorway~* Standing on the toilet~* A sitting pass from the toilet~* One way to a bed~* A sitting pass on the bed~* A passenger seat sitting upright from the bed~* A return to the starting point~* A sitting pass on the starting chair
Study NCT03607461 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smartphone App
Description: Smartphone App Users will engage with the app at least daily and follow along with the prescriptive exercises as instructed.
Study NCT03607461 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Home Health users will have received traditional home health physical therapy and skilled nursing services.
Study NCT01713257 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Immunoenhancing diet
Description: Enteral feeding until Day 10 or the day of discharge if earlier than Day 10. The goal of caloric intake is 25 kcal/kg/day and protein 1.2 g/kg/day.
Study NCT01713257 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Isocaloric, isonitrogenous diet
Description: Enteral feeding until Day 10 or the day of discharge if earlier than Day 10. The goal of caloric intake is 25 kcal/kg/day and protein 1.2 g/kg/day.
Study NCT02791477 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Attune FB PS knee arthroplasty
Study NCT03631394 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: beetroot and anthocyanin
Description: Beetroot and anthocyanin will be taken for 7 days during the study two hours prior to eating.
Study NCT03631394 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: beetroot and placebo
Description: Beetroot and placebo will be taken for 7 days during the study two hours prior to eating.
Study NCT02168660 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: Vitamin D3, liquid formulation, 5000 IU/mL.
Study NCT02168660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Vitamin D3, liquid formulation, 5000 IU/mL.
Study NCT00852761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olux-E Foam
Description: Olux-E (clobetasol propionate 0.05%) foam. Starting at baseline, subjects were to apply twice daily Olux-E foam to the affected elbows and/or knees up to day 15.
Study NCT00852761 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clobex lotion
Description: Clobetasol propionate 0.05% lotion. Starting at baseline, subjects were to apply twice daily Clobex lotion to the affected elbows and/or knees up to day 15
Study NCT00417391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RR110 (Tamibarotene)
Description: 1 mg RR110
Study NCT00417391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RR110 (Tamibarotene)
Description: 4 mg RR110
Study NCT00169338 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation
Description: internal pallidal deep brain stimulation
Study NCT03885674 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video Call Reminder Condition
Description: Receive daily video call reminders from Kessler Foundation research staff directly at the time of each medication dose and instructed to take the medication while on the video call.
Study NCT03885674 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Automated Text Message Reminder Condition
Description: Receive daily automated text messages at the time of each medication dose and will be instructed to take the medication at that time. Each text message reminder will also contain a photo of the medication to be taken. On a weekly basis, study personnel will contact participants in this group to make sure they are receiving the text messages appropriately.
Study NCT02462889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept injection
Description: Intravitreal aflibercept injection
Study NCT02462889 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sham injection